Drug Trial Radar · NCT05664217
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15
Actual
Start
Feb 23, 2023
Primary completion
May 22, 2024
Study completion Aug 16, 2024
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nektar Study 18-255-01 was a Phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 versus placebo following CD19-directed CAR-T cell therapy in patients with R/R LBCL. This study was to be run in 2 parts: Phase 2 (Stage 1) and Phase 3 (Stage 2). This study evaluated the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 was an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 following the treatment with CD19 CAR-T cell therapy may work better in treating large B-cell lymphoma than either drug alone.
Conditions
- Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-cell Lymphoma
Interventions
NKTR-255 at 1.5 µg/kgDrug
NKTR-255 at 1.5 µg/kg
NKTR-255 at 3.0 μg/kgDrug
NKTR-255 at 3.0 μg/kg
NKTR-255 at 3.0/6.0 μg/kgDrug
NKTR-255 at 3.0/6.0 μg/kg
Placebo ComparatorOther
Commercially available 0.9% Sodium Chloride Solution for Injection (USP)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Response (CR) RateTime frame: At month 6
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
University of Kansas Cancer Center
Fairway, Kansas
UMass Memorial Medical Center
Worcester, Massachusetts
Washington University School of Medicine in St. Louis
St Louis, Missouri
NYU Langone Medical Center
New York, New York
Novant Health Cancer Institute
Charlotte, North Carolina
Oncology Hematology Care Inc - Cincinnati
Cincinnati, Ohio
University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.